Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate and Rosuvastatin for Sexual Dysfunction in Hyperlipidemia
NCT00923676Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2008
- Primary completion
- Oct 2015
- Countries
- 1
- Sponsor
- University of Campania Luigi Vanvitelli
- Modality
- Orthosteric Ligands
- Conditions
- sexual dysfunctionhyperlipidemia
01
Overview
Phase 4, randomised, open-label trial of fenofibrate and rosuvastatin in sexual dysfunction and hyperlipidemia, sponsored by University of Campania Luigi Vanvitelli. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Hyperlipidemic patients with sexual dysfunction and a stable heterosexual partner. Excludes those with diabetes, uremia, MS, alcoholism, cancer, psychiatric issues, symptomatic CVD, or specific gynecological/pelvic conditions.
04
Registry description
Hyperlipidemias are frequently associated with and are considered an important cause of erectile dysfunction in men. This association has been attributed to the impairment of blood flow through endothelium-dependent relaxation in smooth muscle cells of corpus cavernosum. Basic science and human research suggest that the vascular pathophysiology of male and female sexual dysfunction may be similar, as the first phase of the female sexual response is mediated by a combination of vasocongestive and neuro-muscular event which include increased clitoral length and diameter, as well as increased…
Beyond the preview
Go deeper on NCT00923676.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923676.